Discovering potent EGFR inhibitors through the structural optimization of the Betti-base scaffold
{{output}}
EGFR is a critical oncogenic driver in non-small cell lung cancer (NSCLC). However, there are no approved inhibitors for the C797S resistance mutation. Allosteric inhibitors targeting a site near the ATP-binding pocket have emerged as a promising alternative. ... ...
